Navigation Links
Global Market for Induced Pluripotent Stem Cells to Reach $2.9 Billion in 2018; Technology Offers New Hope for Regenerating Human Tissue

(PRWEB) July 17, 2014

BCC Research ( reveals in its new report, INDUCED PLURIPOTENT STEM CELLS: GLOBAL MARKETS, the global market for induced pluripotent stem cells (iPSCs) is expected to grow to $2.9 billion by 2018, with a five-year compound annual growth rate (CAGR) of 19.7%. The Asia-Pacific market, the fastest performing regional segment, is projected to move at a significant CAGR of 22%.

iPSCs are a breakthrough technology recognized by the 2012 Nobel Physiology and Medicine Prize. They are expected to bring revolutionary changes to modern medicine and new hope for reprogramming cells to repair damaged tissues in the human body. They are already useful for drug development and modeling of diseases; scientists hope to use them as powerful tools in tissue transplants since they can be developed from a patient's own cells, avoiding the risk of rejection that is often encountered. The technologies of differentiating iPSCs into various tissue cells are also developing rapidly.

Markets and applications for this technology include academic research, drug development and toxicity testing, regenerative medicine, molecular and cellular engineering, cellular reprogramming, and cell culture.

"The clinical research and service iPSCs market is expected to experience rapid growth in the next few years," says BCC Research biotechnology analyst Mike Fan. "Indeed, iPSCs technology is speeding up and improving the drug discovery process, particularly in promoting personal medicine and the development of personalized drugs and diagnostic tests."

iPSCs are artificially derived from non-pluripotent somatic cells by inducing expression of specific genes. Similar to embryonic stem cells, iPSCs possess pluripotency but reduce associated ethical issues by eliminating the use of embryos. Pluripotency refers to the ability to become any tissue in the body, excluding a placenta.

INDUCED PLURIPOTENT STEM CELLS: GLOBAL MARKETS provides an overview of the global market for iPSCs. It includes analyses of global market trends, with data from 2012 and 2013, and projections of CAGRs through 2018, as well as profiles of companies important in the industry.

Editors and reporters, who wish to speak with the analyst, should contact Steven Cumming at steven.cumming(at)bccresearch(dot)com.

About BCC Research

BCC Research publishes market research reports that make organizations worldwide more profitable with intelligence that drives smart business decisions. These reports cover today's major industrial and technology sectors, including emerging markets. For more than 40 years, we have helped customers identify new market opportunities with accurate and reliable data and insight, including market sizing, forecasting, industry overviews, and identification of significant trends and key competitors. We partner with analysts who are experts in specific areas of industry and technology, providing unbiased measurements and assessments of global markets. Our clients include the top companies in industries around the world as well as universities, business schools, start-ups, consulting firms and investment companies. BCC Research is a unit of Eli Research LLC. Visit our website at Contact us: (+1) 781-489-7301 (U.S. Eastern Time), or email information(at)bccresearch(dot)com.

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49-2 Walnut Park, Wellesley, MA 02481, Telephone: (+1) 781-489-7301; Email: editor(at)bccresearch(dotcom as the source and publisher. Thank you.

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
2. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
3. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
4. StemCyte Adds World Class Talent to its North America and Global Operations
5. Sequenom Named to NASDAQ Global Select Market
6. Synthetic Biology: Emerging Global Markets
7. MacroGenics Receives Milestone Payment as Part of Its Global DARTâ„¢ Alliance with Boehringer Ingelheim
8. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
9. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
10. MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016
11. Accuray Surpasses 600 Installations Globally
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... of IIROC on behalf of the Toronto Stock Exchange, ... release there are no corporate developments that would cause ... --> --> About Aeterna ... . --> Aeterna Zentaris is a ...
Breaking Biology Technology:
(Date:11/18/2015)... Nov. 18, 2015  As new scientific discoveries deepen ... and other healthcare providers face challenges in better using ... patients. In addition, as more children continue to survive ... adulthood and old age. John M. Maris, ... Hospital of Philadelphia (CHOP) . --> ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
Breaking Biology News(10 mins):